Cala, a leader in bioelectronic medicine, has received U.S. Food and Drug Administration clearance for its Cala kIQ Plus system. This next-generation wearable device is designed to provide temporary relief from action hand tremors for adults with essential tremor and Parkinson's disease. The system introduces advanced technology to offer a more personalized and effective non-invasive treatment option for patients.
Advancements in Wearable Neuromodulation
The newly cleared Cala kIQ Plus system builds upon its predecessor with significant technological enhancements. It introduces new therapy modes and an adaptive calibration feature designed to optimize tremor relief based on individual patient needs. These advancements aim to provide a more intuitive and personalized experience, giving users greater control over their treatment.
At the core of the device is Cala's proprietary Transcutaneous Afferent Patterned Stimulation (TAPS) technology. Worn on the wrist, the system measures a patient's specific tremor patterns and delivers calibrated electrical stimulation to peripheral nerves. This non-invasive approach targets the brain networks responsible for tremors, offering a sophisticated alternative to medications or surgical procedures.
Clinical Efficacy and Upcoming Data
Cala is set to present clinical data supporting the device's improved efficacy at the upcoming American Academy of Neurology conference. The research, which involved 78 patients, evaluated several variations of the TAPS therapy over a six-week period. Results from the study demonstrated that all tested therapy modes provided a significant reduction in tremor severity.
The study highlighted that a burst-frequency variation (BFV) mode significantly increased the proportion of patients achieving a clinically rated functional benefit. This mode saw 89.3% of patients improve, compared to 80.4% with the standard mode. Researchers also noted a bilateral effect, with tremor improvement observed in both the stimulated and non-stimulated arms.
Patient Access and Market Impact
The FDA clearance marks a pivotal moment for patients seeking better ways to manage their condition. Cala CEO Deanna Harshbarger stated that the system gives patients more control over how and when therapy is delivered for tremor management. This innovation empowers individuals to manage a symptom that can significantly impact daily activities and quality of life.
The Cala system is currently available to eligible beneficiaries through the Veterans Affairs (VA) Health System at no cost. It also has Medicare coverage for patients who meet specific local coverage criteria. The company continues to advocate for expanded reimbursement to include Medicare Advantage and other commercial insurance plans.
The FDA clearance of the Cala kIQ Plus system represents a meaningful advancement in the field of wearable neuromodulation. By offering a personalized, non-invasive, and effective solution, the device provides new hope for individuals living with essential tremor and Parkinson's disease. This development underscores the growing potential of bioelectronic medicine to transform the standard of care for chronic conditions.